Subgroup analysis showed that the association between overexpressed PODXL and poor OS in patients with cancers, was only significative in the glioblastoma multiforme, pancreatic cancer, renal cell carcinoma, colorectal cancer and urothelial bladder cancer, but not in the esophageal cancer, gastric cancer and lung adenocarcinoma. This evidence concerns the gene PODXL and esophageal cancer.